Agenus Inc Dossier - Source-backed chat

Agenus Inc

AGENNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.21

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $9.93Price as of 30 Sep 2026

Data confidence Sign in to view data confidence

Market Cap $448.5M

Enterprise Value $459.8M

Shares Outstanding 43.6M diluted

Next Earnings Date12 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Agenus Inc. is transitioning from a clinical-stage foundation to active execution of its lead next-generation immunotherapy combination, botensilimab (BOT) and balstilimab (BAL). The company has successfully improved its short-term liquidity through a strategic $91 million manufacturing asset sale to Zydus Lifesciences and is generating early pre-commercial revenues via global early access programs. While going-concern risks remain elevated due to a substantial accumulated deficit, the initiation of the global Phase 3 BATTMAN trial in refractory microsatellite stable (MSS) metastatic colorectal cancer (mCRC) provides a clear registrational pathway in a high-unmet-need oncology market.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$30.00

Mean target$30.00

High · most bullish analyst$30.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 19 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$6.0020%

Regulatory filings for BOT+BAL face delays or require additional randomized data prior to submission. The company struggles to secure non-dilutive partnering capital, forcing heavy reliance on highly dilutive equity issuances under its ATM program, which depresses the stock price amid persistent going-concern warnings from auditors.

Base CaseCentral scenario

$15.5050%

Agenus steadily advances the BATTMAN trial and files for U.S. Accelerated Approval based on mature Phase 2 data. The company maintains its disciplined $50 million annualized operating expense framework, utilizing its at-the-market equity program and milestone payments to extend its cash runway into 2027 while seeking regional collaborations.

Bull CaseUpside scenario

$23.0030%

BOT+BAL achieves rapid enrollment in the Phase 3 BATTMAN trial and demonstrates superior overall survival in refractory MSS mCRC, leading to accelerated FDA approval. Early access revenues expand significantly across Europe and South America, while a major regional pharmaceutical partnership is secured, fully funding operations past 2027 and eliminating going-concern doubts.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Differentiated next-generation Fc-enhanced CTLA-4 antibody (botensilimab) showing clinical activity across nine metastatic, late-line cold tumors.
Established pre-commercial revenue stream ($4.6 million in Q1 2026) from regulatory-authorized early access and named-patient programs.
Strategic collaboration with Zydus Lifesciences secured dedicated U.S. biologics manufacturing capacity and provided $91 million in upfront capital.
Significant reduction in core R&D and G&A expenses (down 45% and 56% YoY in Q1 2026) following corporate realignment.

Key Investment Risks

High financial risk with an accumulated deficit of $2.14 billion as of March 31, 2026, and ongoing going-concern uncertainty.
Clinical and regulatory dependency on the success of the BOT+BAL combination in historically immunotherapy-resistant MSS mCRC.
Potential for safety signals or lower-than-expected efficacy to emerge as clinical trials expand to larger patient cohorts.

Thesis Invalidation Triggers

Failure of the Phase 3 BATTMAN trial to meet its primary survival endpoints.
FDA refusal to file or accept the planned 2026 Accelerated Approval submission for BOT+BAL.
Inability to secure additional capital or strategic partnerships before the current cash runway is exhausted in early 2027.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.